On November 13, 2026 Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, reported positive clinical data from its ongoing Phase 1/1b study in adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN) and a subset of patients with cutaneous neurofibromas (cNF) (Study PAS-004-103, NCT06961565), presented at the 2026 European Neurofibromatosis Conference in Vienna, Austria.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Cutaneous neurofibromas do not regress spontaneously and generally increase in number and size with age. The substantial reductions in cNF size reported today represent an encouraging clinical signal in a condition for which there are currently no FDA-approved systemic treatments," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. "Importantly, these reductions have continued to deepen with longer treatment, including at the lowest doses tested. With our IND now cleared by FDA’s Division of Dermatology and Dentistry, these findings reinforce our confidence in the 4mg to 12mg dose range planned for Phase 2 and support advancing PAS-004 into a randomized, placebo-controlled study in cNF."

"The reductions in cNF size observed with oral PAS-004 highlight its potential to provide broad, visible improvements for patients through a systemic treatment approach, rather than relying on local procedures that can treat individual lesions," said Dr. Kartik Krishnan, Chief Medical Officer of Pasithea. "We are also seeing early activity in plexiform neurofibromas, with reductions in tumor volume across all dose levels and two participants meeting the REiNS threshold for partial response, including one at the first on-treatment MRI. Together with the favorable tolerability observed to date and a pharmacokinetic profile characterized by a 40-to-60-hour half-life and limited peak-to-trough fluctuations, these findings support the continued development of PAS-004 as a once-daily oral therapy for long-term treatment of NF1-associated neurofibromas."

Pasithea will post a webcast on Friday, November 13, 2026, at 7:00 a.m. EST to discuss the PAS-004 clinical data presented at the 2026 European Neurofibromatosis Conference. The webcast will be accessible here and through the Investors section of the Company’s website.

Study Overview

Study PAS-004-103 is an ongoing multicenter, open-label Phase 1/1b trial in adults with NF1 and symptomatic and inoperable, incompletely resected, or recurrent PN at five sites in the United States, Australia and South Korea. The study also evaluates up to 7 cNFs in participants with measurable lesions. Part A studies six escalating doses using a 3+3 design to select two doses for evaluation in Part B, a randomized dose expansion phase. The study also assesses safety, tolerability, pharmacokinetics and pharmacodynamics.

As of September 15, 2026, 19 participants have been enrolled across six cohorts (4, 8, 12, 15, 18 and 24mg). Of these, 15 were evaluable for cNF and 18 for PN response. Median treatment duration ranged from 14.4 months at 4mg to approximately 4 months at 15mg and 24mg. One participant discontinued by sponsor decision for noncompliance, unrelated to safety.

Cutaneous Neurofibroma (cNF) Data

Fifteen participants were evaluable for cNF, with 71 target cNFs measured at baseline. Length and width of each target cNF were measured in triplicate with digital calipers. As there is no regulatory standard for assessing cNFs, both surface area (calculated from length and width) and longest diameter (the REiNS-recommended caliper measure) are reported.

Substantial Reductions in cNF Surface Area (Figure 1)

Reductions Across All Doses: All 15 evaluable participants showed reductions in summed target cNF surface area at best response, with a median best reduction of 41%.

Activity at Planned Phase 2 Doses: Among eight evaluable participants treated at 4, 8 and 12mg, the median best reduction was 46%. All six participants treated at 4mg and 8mg achieved reductions greater than 40%.

Safety and Tolerability

No treatment-related serious adverse events, discontinuations, adverse events of decreased LVEF, or cases of retinopathy have been reported. Most treatment-related adverse events were Grade 1 or 2 (97.6% of events). The two Grade 3 treatment-related events were asymptomatic increases in blood creatine phosphokinase (CPK), both of which resolved following a one-week dose interruption, with both participants continuing treatment. At the 4 to 12mg doses planned for Phase 2, dermatitis acneiform (rash) and diarrhea occurred in 33% and 11% of participants, respectively (data cut-off: September 15, 2026).

Pharmacokinetics

PAS-004 showed approximately dose-proportional exposure across the 4 to 24mg range, a terminal half-life of 40 to 60 hours, and limited peak-to-trough fluctuations (Cmax/Cmin of 1.5 to 2.0), consistent with findings from the Company’s ongoing Phase 1 study in advanced solid tumors and supporting once-daily dosing (data cut-off: October 7, 2026).

Next Steps

The FDA’s Division of Dermatology and Dentistry has cleared the IND for Study PAS-004-201, a randomized, double-blind, placebo-controlled Phase 2 trial evaluating three once-daily doses of PAS-004 in approximately 200 adults with NF1-associated cNF.

The ongoing Phase 1/1b study (PAS-004-103) will continue participant follow-up and advance toward Part B, a randomized two-dose expansion phase. The Company expects to complete pharmacodynamic analyses of resected cNFs in 2027 and present additional clinical data at future scientific meetings.

About Cutaneous Neurofibromas (cNF)

NF1-associated cutaneous neurofibromas (cNFs) are benign tumors that grow in or just beneath the skin at virtually any location in the body and are a hallmark of NF1. It is a serious condition and cNFs are associated with significant morbidity that can have substantial impact on day-to-day functioning, leading patients to rate this as the most significant burden of NF1 despite other potentially life-threatening complications. cNF typically begin to appear in adolescence, generally increase in number and volume with age. The number of cNFs on an individual patient can range from a few to thousands. Although malignant transformation does not occur with NF1-associated cNF, cNFs are present in over 95% of individuals with NF1 and have a significant negative impact both physically, with disfigurement, and on health-related quality of life. Current management relies largely on procedural approaches such as surgical excision, electrodesiccation, or laser therapy. There are no FDA-approved systemic therapies for the treatment of NF1-associated cNF.

About Plexiform Neurofibromas (PN)

NF1-associated plexiform neurofibromas (PNs) are tumors originating from the nerve sheath that grow through and around nerves and may involve multiple nerve branches. Thirty to fifty percent (30-50%) of patients with NF1 will harbor PNs, which can undergo malignant transformation. PN-related morbidities, including pain, disfigurement and functional impairment are primarily caused by the direct impact of the tumor on surrounding structures and can be life-threatening when they compress vital organs or when they become malignant.

(Press release, Pasithea Therapeutics, NOV 13, 2026, View Source [SID1234674774])